CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

被引：7
|
作者：
Ramachandran, Raja [1 ]
Yadav, Ashok K. [1 ]
Kumar, Vinod [1 ]
Gupta, Krishan L. [1 ]
Kohli, Harbir S. [1 ]
机构：
[1] PGIMER, Dept Nephrol, Chandigarh, India
来源：
KIDNEY INTERNATIONAL REPORTS | 2017年 / 2卷 / 01期
关键词：
D O I：
10.1016/j.ekir.2016.08.019
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：89 / 90
页数：2
相关论文
共 23 条
  • [21] ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODY (PLA2R)-NEGATIVE MEMBRANOUS NEPHROPATHY ASSOCIATED WITH OMENTAL MESOTHELIOMA AND RETROPERITONEAL FIBROSIS
    Cohen, A.
    Vilayur, E.
    NEPHROLOGY, 2021, 26 : 49 - 50
  • [22] Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab
    Sun, Jingshu
    Wu, Shengqin
    Yin, Fang
    Zhang, Kunying
    Wang, Jianying
    CLINICAL NEPHROLOGY, 2024, 103 (01) : 63 - 68
  • [23] Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Deng, Biping
    Chang, Alex Hongsheng
    Yang, Junfang
    Pan, Jing
    Zhang, Xian
    Lin, Yuehui
    Wu, Yanan
    Deng, Zhenling
    Lu, Peihua
    Wu, Tong
    Liu, Zhaoli
    Zhang, Yu'e
    Tong, Chunrong
    BLOOD, 2016, 128 (22)
123